

Contents

CHAPTER 1

Classification of Epileptic Seizures and the Epilepsies and Drugs of Choice for Their Treatment

F.E. DREIFUSS and N.B. FOUNTAIN	1
A. Introduction	1
B. The International Classification of Epileptic Seizures	3
I. Partial Seizures	3
II. Generalized Seizures	3
C. Classification of the Epilepsies and Epileptic Syndromes	5
I. Idiopathic Epilepsies	5
1. Idiopathic Epilepsies with Partial Seizures	5
2. Idiopathic Epilepsies with Generalized Seizures	7
II. Symptomatic Epilepsies	7
1. Symptomatic Epilepsies with Partial Seizures	7
2. Symptomatic Epilepsies with Generalized Seizures	8
III. Epilepsies That Are Difficult to Categorize	8
1. West's Syndrome	8
2. Lennox-Gastaut Syndrome	9
3. Acquired Epileptic Aphasia (the Landau-Kleffner Syndrome)	9
4. Epilepsy with Continuous Spike-Wave during Slow Wave Sleep	9
D. Influence of Technological Advances on the Understanding of Semiology	9
I. Singular Nuclear Gene Disorders	9
II. Complex Inheritance Disorders	10
E. Drugs of Choice for Epileptic Seizures and the Epilepsies	10
I. Drugs for Epileptic Seizures	11
1. Partial Seizures	11
2. Generalized Seizures	12
II. Drugs for the Epilepsies	13
1. Idiopathic Epilepsies with Partial Seizures	13
2. Idiopathic Epilepsies with Generalized Seizures	14

3. Symptomatic Epilepsies with Localization-Related Seizures	14
4. Symptomatic Epilepsies with Generalized Seizures	14
5. Febrile Convulsions	15
F. Conclusion	15
References	15

CHAPTER 2

Animal Models of Epilepsy and Epileptic Seizures

W. LÖSCHER. With 1 Figure	19
A. Introduction	19
B. Animal Models of Epilepsy	21
I. Localization-Related (Focal, Local, Partial) Epilepsies	24
1. Idiopathic (Primary) Focal Epilepsies	24
a) Dogs with Idiopathic Localization-Related Epilepsy	25
2. Symptomatic (Secondary) Focal Epilepsies	26
a) The Kindling Model of Temporal Lobe Epilepsy	27
b) The Kainate Model	31
c) The Pilocarpine Model	31
d) Chronic Epilepsy Following Status Epilepticus	32
e) Spontaneous Focal Seizures Following Local Application of Metals, Chemical Convulsants or Toxins	33
II. Generalized Epilepsies	33
1. Animal Models of Idiopathic Primary Generalized Epilepsies	34
a) Epileptic Dogs	34
b) Rats with Generalized Absence Epilepsy	34
c) The Lethargic (lh/lh) Mouse	35
d) The Spontaneously Epileptic Double Mutant Rat	36
e) Transgenic or Knockout Mice	36
III. Undetermined Epilepsies	37
1. Tottering Mice	37
IV. Special Syndromes	38
a) Epileptic Gerbils	38
b) Audiogenic Seizure Susceptible Mice	39
c) Audiogenic Seizure Susceptible Rats	40
d) Epileptic Baboons with Photomyoclonic Seizures	41
e) El Mice	43
C. Animal Models of Epileptic Seizures	43

I. Animal Models of Partial (Focal, Local) Seizures	44
1. Epileptic Animals with Focal Seizures	44
2. Focal Seizures Induced in Normal, Non-epileptic Animals	48
II. Animal Models of Generalized Seizures	50
1. Epileptic Animals with Primary Generalized Seizures	50
a) Genetic Animal Models of Epilepsy with Generalized Convulsive Seizures	50
b) Genetic Animal Models of Epilepsy with Generalized Non-convulsive Seizures)	50
2. Primary Generalized Seizures Induced in Normal, Non-epileptic Animals	51
a) Models of Convulsive Seizures	51
b) Models of Absence or Myoclonic Seizures	53
D. Conclusions	55
References	56

CHAPTER 3

Epileptogenesis: Electrophysiology

J.O. WILLOUGHBY. With 7 Figures	63
A. Introduction	63
B. Partial (Focal, or Lesional) Epilepsy	64
I. Overview	64
II. The Single Neuron: Normal Population	64
III. The Single Neuron: Epileptic Population	67
IV. Connectivity	68
V. Other Processes	70
C. Generalized Epilepsy: Absence Seizures	71
I. Overview	71
II. Cortical Processes	73
III. Thalamic Processes	73
IV. Human Studies	74
D. Generalized Epilepsy: Convulsive Seizures	75
I. Overview	75
II. Excessive Excitation or Impaired Inhibition	76
III. Anatomical Distribution of Convulsions: Cortex and Hippocampus	76
IV. Electrophysiological Distribution of Convulsions: Cortex and Brain Stem	77
V. Human Studies: Predisposing Brain Processes and a Synthesis	79
References	81

CHAPTER 4

Epileptogenesis: Biochemical Aspects

B. JARROTT	87
A. Introduction	87
B. Methods for Studying Epileptogenesis	87
I. In Humans	87
1. Imaging Techniques	87
2. Neurophysiological Studies on Cortical Slices Maintained In Vitro	88
3. Microdialysis	88
II. Animal Models	88
1. Kindling	88
2. Kainate Model	89
3. Genetic Strains	89
III. Biochemical Techniques	89
C. Role of Neurotransmitters in Epileptogenesis	90
I. Amino Acids	90
1. L-Glutamate	90
a) Glutamate Release and Reuptake	90
b) Glutamate Receptors	91
α) NMDA Receptors	92
β) AMPA/Kainate Receptors	93
γ) Metabotropic Glutamate Receptors	94
2. GABA	94
a) GABA Synthesis and Storage	94
b) GABA Transporters	96
c) GABA Receptors	96
α) GABA _A Receptors	96
β) GABA _B Receptors	97
II. Biogenic Amines	98
1. Noradrenaline	98
2. 5-Hydroxytryptamine	100
3. Acetylcholine	100
III. Neuropeptides	101
1. Neuropeptide Y	102
2. Somatostatin	102
3. Cholecystokinin	103
4. Dynorphin	103
IV. Purines	103
V. Nitric Oxide	105
D. Postsynaptic Effects	106
I. Role of Ca ²⁺ Channels and Ca ²⁺ Binding Proteins	106
II. Immediate Early Genes	107
E. Neurotrophins and Neurogenesis	110

I. Mossy Fibre Sprouting in the Hippocampus	111
II. Neuronal Migration Disorders in the Cortex	114
F. Conclusions	114
References	114

CHAPTER 5

Cellular Actions of Antiepileptic Drugs

R.L. MACDONALD	123
A. Introduction	123
B. Established Antiepileptic Drug Mechanisms of Action	123
I. Phenytoin and Carbamazepine	123
II. Benzodiazepines and Barbiturates	125
III. Ethosuximide and Trimethadione	127
IV. Valproic Acid	129
C. Newly Developed Antiepileptic Drug Mechanisms of Action	129
I. Gabapentin	129
II. Lamotrigine	132
III. Oxcarbazepine	134
IV. Vigabatrin	135
V. Tiagabine	137
VI. Topiramate	138
VII. Felbamate	139
References	141

CHAPTER 6

The Search for New Anticonvulsants

D. SCHMIDT	151
A. Introduction	151
B. Pharmacological Strategies in the Search for New Anticonvulsants	152
I. Rational Drug Design	157
1. Selective Enhancement of GABAergic Neurotransmission	157
2. Selective Attenuation or Blockade of Excitatory Aminoacidergic Neurotransmission	159
3. Selective Modulation of Ion Channels	159
4. Other Strategies for Rational Drug Design	160
II. Random Screening or Molecular Structural Variation of Known Compounds	160
1. Retigabine	161
2. TV 1901	161

3. Dezinamide	161
4. MDL 27,192	161
C. Clinical Evaluation of Preclinical Development Strategies	161
D. Strategies for Future Drug Development	163
I. Chemical Systems for Delivery of Antiepileptic Drugs to Regions of the Brain	164
II. Rational Polytherapy	164
III. Predictive Identification of Responders	165
IV. Strategies for the Development of Drugs for Unresponsive Epilepsies	165
V. Identification of Genetic Defects in Epilepsy	165
E. Conclusions	165
References	168

CHAPTER 7

Measurement of Anticonvulsants and Their Metabolites in Biological Fluids

W.D. HOOPER and L.P. JOHNSON	173
A. Introduction	173
B. Chromatographic Methods	173
I. Gas Chromatography and High Performance Liquid Chromatography	174
C. Capillary Electrophoresis and Micellar Electrokinetic Capillary Electrophoresis	175
I. Antiepileptic Drug Analysis by Capillary Electrophoresis and Micellar Electrokinetic Capillary Electrophoresis	176
D. Stereoselective Drug Analysis	177
E. Immunoassay Methods	178
I. Immunoassay Instrumentation	179
II. Analytical Performance	180
III. Non-laboratory Immunoassay Antiepileptic Drug Monitoring	181
F. Free Drug Monitoring	181
I. Saliva	182
G. Quality Assurance	183
References	183

CHAPTER 8

Older Anticonvulsants Continuing in Use but with Limited Advance in Knowledge

M.J. EADIE and F.J.E. VAJDA. With 2 Figures	189
---	-----

A. Introduction	189
B. Phenobarbitone and Congeners	189
I. Chemistry and Use	189
1. Chemistry	189
2. Use	190
II. Pharmacodynamics	190
1. Animal Models of Epilepsy	190
2. Electrophysiological Actions	191
3. Biochemical Actions	191
III. Pharmacokinetics	191
1. Absorption	191
a) Phenobarbitone	191
b) Methylphenobarbitone	192
c) Primidone	192
2. Distribution	192
a) Phenobarbitone	192
b) Methylphenobarbitone	192
c) Primidone	193
3. Elimination	193
a) Metabolism	193
α) Phenobarbitone	193
β) Methylphenobarbitone	195
γ) Primidone	195
b) Elimination Parameters	196
α) Phenobarbitone	196
β) Methylphenobarbitone	196
γ) Primidone	196
4. Applied Pharmacokinetics	197
a) Phenobarbitone	197
b) Methylphenobarbitone	197
c) Primidone	198
IV. Interactions	198
1. Pharmacodynamic Interactions	198
2. Pharmacokinetic Interactions	199
a) Phenobarbitone Affecting Other Substances	199
b) Other Substances Affecting Phenobarbitone	199
α) Methylphenobarbitone	200
β) Primidone	200
V. Adverse Effects	200
1. Idiosyncratic Effects	200
2. Dose-Determined Effects	201
3. Effects on the Foetus and Neonate	202
C. Succinimides	202
I. Chemistry and Use	202

1. Chemistry	202
2. Use	203
II. Pharmacodynamics	203
1. Animal Models of Epilepsy	203
2. Electrophysiological Studies	204
3. Biochemical Effects	204
III. Pharmacokinetics	204
1. Absorption	204
2. Distribution	205
3. Elimination	205
a) Metabolism	205
b) Elimination Parameters	206
4. Applied Pharmacokinetics	207
IV. Interactions	207
1. Pharmacodynamic Interactions	207
2. Pharmacokinetic Interactions	208
V. Adverse Effects	208
D. Sulthiame	208
I. Chemistry and Use	208
II. Pharmacodynamics	209
III. Pharmacokinetics	209
IV. Interactions	210
V. Adverse Effects	210
E. Acetazolamide	210
I. Chemistry and Use	210
II. Pharmacodynamics	211
III. Pharmacokinetics	211
IV. Interactions	212
V. Adverse Effects	212
F. Bromides	212
I. Chemistry and Use	212
II. Pharmacodynamics	213
III. Pharmacokinetics	213
IV. Interactions	213
V. Adverse Effects	213
References	213

CHAPTER 9

Phenytoin and Congeners

H. KUTT and C.L. HARDEN. With 1 Figure	229
A. Phenytoin	229
I. Introduction	229
II. Chemistry and Use	229

1. Chemistry	229
2. Indications and Use	230
III. Pharmacodynamics	230
IV. Pharmacokinetics	232
1. Absorption	232
2. Distribution	232
3. Elimination	233
a) Metabolism	233
α) Pharmacogenetics	235
b) Elimination Parameters	236
4. Clinical Pharmacokinetics	236
a) Dose-Plasma Level Relationships	236
b) Plasma Level-Effects Relationships	236
α) Beneficial Effects	236
β) Acute Toxic Effects	237
γ) Initial Target Range Concentration	237
V. Interactions	237
VI. Adverse Effects	238
1. Acute Toxicity	238
2. Idiosyncratic Adverse Effects	240
3. Teratogenicity	240
a) Folate, Anaemia, Teratogenesis	241
b) Mechanisms of Idiosyncratic Toxicity and Teratogenicity	241
4. Chronic Toxicity	242
a) Enzyme Induction	243
B. Fosphenytoin	243
I. Introduction	243
II. Chemistry and Use	243
1. Chemistry	243
2. Indications and Use	244
III. Pharmacodynamics	245
IV. Pharmacokinetics	245
1. Absorption and Disposition	245
2. Metabolism	245
3. Clinical Pharmacokinetics	246
V. Adverse Effects	246
C. Mephenytoin	246
I. Introduction	246
II. Chemistry and Use	247
1. Chemistry	247
2. Indications and Use	248
III. Pharmacodynamics	248
IV. Pharmacokinetics	248
1. Absorption and Disposition	248

2. Metabolism	249
a) Pharmacogenetics	249
3. Clinical Pharmacokinetics	250
a) Dose-Plasma Level Relationships	250
b) Plasma Level-Effect Relationships	251
α) Beneficial Effects	251
β) Acute Toxic Effects	251
V. Interactions	251
VI. Adverse Effects	251
D. Ethotoin	252
I. Introduction	252
II. Chemistry and Use	253
1. Chemistry	253
2. Indications and Use	253
III. Pharmacodynamics	253
IV. Pharmacokinetics	253
1. Absorption and Disposition	253
2. Metabolism	254
3. Clinical Pharmacokinetics	254
a) Dose-Plasma Level Relationships	254
b) Plasma Level-Effects Relationships	255
α) Beneficial Effects	255
β) Acute Toxic Effects	255
V. Interactions	255
VI. Adverse Effects	255
E. Phenacetamide	255
I. Introduction	255
II. Chemistry and Use	256
1. Chemistry	256
2. Indications and Use	256
III. Pharmacodynamics	256
IV. Pharmacokinetics	257
1. Absorption and Disposition	257
2. Metabolism	257
3. Clinical Pharmacokinetics	257
a) Dose, Plasma Level and Effect Relationships	257
V. Interactions	257
VI. Adverse Effects	258
F. Albutoin	258
I. Introduction	258
II. Chemistry and Use	258
III. Pharmacology	258
1. Animal Pharmacology	258
2. Human Use	259
References	259

CHAPTER 10

Carbamazepine

R.G. DICKINSON, M.J. EADIE and F.J.E. VAJDA. With 1 Figure	267
A. Introduction	267
B. Chemistry and Use	267
I. Chemistry	267
II. Use	268
C. Pharmacodynamics	268
I. Biochemical Effects	269
1. Ion Channels and Receptors	269
a) Na ⁺ Channels	269
b) Benzodiazepine Receptors	269
c) Ca ²⁺ Channels	269
d) Adenosine Receptors	270
2. Effects on Neurotransmitters	270
a) GABA	270
b) Catecholamines	270
c) Serotonin	270
d) Acetylcholine	271
e) Substance P	271
f) Glutamate	271
g) Somatostatin	271
3. Other Biochemical Changes	271
II. Electrophysiological Effects	271
1. Effects at the Cellular Level	271
2. Effects on Neuronal Pools	272
III. Effects in Animal Models of Epilepsy	273
1. Models of Generalized Epilepsy	273
2. Models of Partial Epilepsy	273
IV. Human Studies	274
D. Pharmacokinetics	274
I. Absorption	275
II. Distribution	276
1. Apparent Volume of Distribution	276
2. Plasma Protein Binding	276
3. Body Fluid and Tissue Distribution	277
a) Blood	277
b) Cerebrospinal Fluid	277
c) Saliva	277
d) Milk	277
e) Foetal Blood and Amniotic Fluid	277
f) Body Tissues	277
III. Elimination	278
1. Metabolism	278

2. Elimination Parameters	280
a) Half-life	280
b) Clearance	281
c) Carbamazepine-10,11-epoxide	281
IV. Clinical Pharmacokinetics	281
a) Pregnancy	283
b) Disease States	283
E. Interactions	284
I. Pharmacodynamic Interactions	284
II. Pharmacokinetic Interactions	284
1. Interactions Which Lower Plasma Carbamazepine Concentrations	284
2. Interactions Which Raise Plasma Carbamazepine Concentrations	285
3. Interactions in Which Carbamazepine Lowers the Plasma Concentrations, or Increases the Clearances, of Other Drugs	286
4. Interactions Leading to Raised Concentrations of Other Drugs	286
F. Adverse Effects	287
I. Biochemical Abnormalities	287
II. Dose-Determined Adverse Effects	287
1. Hyponatraemia	288
III. Idiosyncratic Adverse Effects	288
1. Aromatic Anticonvulsant Hypersensitivity Syndrome	289
2. Skin	289
3. Nervous System	289
4. Haematological	290
5. Cardiovascular	290
6. Respiratory	290
7. Alimentary Tract	290
8. Liver	291
9. Pancreas	291
10. Kidneys	291
11. Bone	291
12. Porphyria	291
13. Thyroid	291
IV. Foetal Toxicity	291
References	292

CHAPTER 11

Oxcarbazepine

S.C. SCHACHTER. With 1 Figure	319
-------------------------------------	-----

A. Introduction	319
B. Chemistry and Use	319
C. Pharmacodynamics	319
I. Biochemical Pharmacology	319
II. Animal Models of Epilepsy	320
III. Human Epilepsies	321
1. Monotherapy Trials	321
a) Controlled Monotherapy Trials in Newly Diagnosed or Previously Untreated Patients	321
α) Study Designs	321
β) Enrolment Information	321
γ) Results	322
δ) Conclusions	323
b) Pre-surgery Trials	323
2. Add-on and Open-label, Long-term Trials	323
D. Pharmacokinetics	324
I. Absorption, Bioavailability, and Distribution	324
II. Elimination	324
1. Metabolism	324
2. Elimination Parameters	324
III. Clinical Pharmacokinetics	324
1. Special Patient Groups	325
a) Hepatic and Renal Impairment	325
b) The Elderly and Children	325
E. Interactions	325
I. Effects on Other Drugs	325
II. Effects of Other Drugs on Oxcarbazepine	325
F. Adverse Effects	326
I. Animal Studies	326
1. Acute Exposure	326
2. Teratogenicity/Carcinogenicity/Mutagenicity	326
II. Human Studies	326
1. Add-on, Open-label Trials	326
2. Monotherapy Trials in Newly Diagnosed or Previously Untreated Patients	326
III. Particular Adverse Effects in Humans	327
1. Rashes	327
2. Overdosage	328
IV. Laboratory Abnormalities	328
V. Pregnancy	328
References	328

CHAPTER 12

Lamotrigine

M.C. WALKER and J.W.A.S. SANDER	331
---------------------------------------	-----

A. Introduction	331
B. Chemistry and Use	331
I. Chemistry	331
1. Analytical Methods	331
II. Use	332
C. Pharmacodynamics	333
I. Anticonvulsant Effects	333
1. Animal Models of Epilepsy	333
a) Maximal Electroshock Seizures	333
b) Chemoconvulsant Tests	333
c) Afterdischarge Tests	334
d) Electrically Induced Kindling	334
e) Genetic Seizure Models	335
f) Models of Status Epilepticus	335
2. Mechanism of Action	336
a) Neurochemical Actions	336
b) Ionic Conductances	337
α) Na^+ Channels	337
β) Ca^{2+} Channels	339
γ) K^+ Channels	339
c) Ligand Binding to Receptors	339
II. Other Central Nervous System Effects	340
1. Effects on the EEG and Sleep	340
2. Memory and Long-Term Potentiation	340
3. Excitotoxic and Ischaemic Neuronal Injury	341
4. Effects on Involuntary Movement Disorders	342
5. Morphine Withdrawal	343
6. Increased Atmospheric Pressure	344
7. Anxiolytic Effects	344
III. Effects Outside the Central Nervous System	344
1. Effects on Peripheral Nerves and Analgesic Effects	344
2. Other Effects	345
D. Pharmacokinetics	345
I. Absorption	345
II. Distribution	346
III. Elimination	347
1. Elimination Parameters	347
2. Metabolism	348
IV. Clinical Pharmacokinetics	348
E. Interactions	349
I. Pharmacodynamic Interactions	349
II. Pharmacokinetic Interactions	349
F. Adverse Effects	350

I. Animal Toxicity	350
II. Human Toxicity	351
References	352

CHAPTER 13

Valproate

D.D. SHEN and R.H. LEVY	359
A. Introduction	359
B. Chemistry and Use	359
I. Chemistry	359
II. Use	359
C. Pharmacodynamics	360
I. Experimental Animal Studies	360
II. Biochemical Pharmacology	360
D. Pharmacokinetics	362
I. Absorption	362
II. Distribution	363
III. Elimination	364
1. Clearance Parameters	364
2. Metabolism	366
E. Interactions	367
I. Other Drugs Affecting Valproate	367
II. Valproate Affecting Other Drugs	368
F. Adverse Effects	369
References	369

CHAPTER 14

Vigabatrin

E. BEN-MENACHEM. With 1 Figure	375
A. Chemistry and Use	375
I. Chemical Characteristics	375
1. Enantiomers	375
II. Use	375
B. Pharmacodynamics	375
I. Biochemical Pharmacology	375
1. Effects on GABA and Other Amino Acids	375
II. Animal Models	376
1. Anticonvulsive Effects	376
2. Prevention of Epileptogenesis	377
3. Neuroprotective Effects	377

III. Humans	377
1. CSF and Brain Concentrations of GABA and Other Amino Acids	377
2. Magnetic Resonance Spectroscopy	378
3. Effects on Platelets	379
4. Human Epilepsy	379
a) Adults with Partial Seizures	379
α) Major Single-Blind Studies	379
β) Major Double-Blind Studies	379
γ) Monotherapy Studies	382
δ) Long-term Studies	382
b) Children with Partial Seizures	382
c) Children with Infantile Spasms	383
d) Children with the Lennox-Gastaut Syndrome	383
C. Pharmacokinetics	384
I. Absorption and Bioavailability	384
II. Distribution	384
1. Body Tissues and Fluids	384
2. Placental Transfer	384
III. Elimination	385
1. Metabolism	385
2. Elimination Parameters	385
IV. Clinical Pharmacokinetics	385
D. Interactions	385
E. Adverse Effects	386
I. General Effects	386
II. Psychosis	386
III. Visual Field Defects	388
IV. Teratogenicity	388
F. Use in Clinical Practice	389
I. Dosage	389
II. Dose Titration	389
III. Laboratory Monitoring	389
References	390

CHAPTER 15

Benzodiazepines

C. KILPATRICK. With 1 Figure	395
A. Introduction	395
B. Pharmacodynamics of Benzodiazepines in General	395
I. Animal Models of Epilepsy	395
II. Biochemical Pharmacology	396
C. Benzodiazepine Adverse Effects and Their Mechanisms	397

D. Diazepam	399
I. Chemistry	399
II. Pharmacodynamics	399
1. Humans	399
III. Pharmacokinetics	400
1. Absorption	400
2. Distribution	400
a) Cerebrospinal Fluid	400
b) Brain	401
c) Plasma Protein Binding	401
3. Elimination	401
a) Metabolism	401
b) Elimination Parameters	402
c) Excretion	403
4. Clinical Pharmacokinetics	403
a) Plasma Concentration: Clinical Effect Relationships	405
b) Treatment of Status Epilepticus	405
IV. Interactions	406
V. Adverse Effects	406
E. Clobazam	407
I. Chemistry	407
II. Pharmacodynamics	407
1. Mechanism of Action	407
2. Animal Models	408
3. Human Studies	408
III. Pharmacokinetics	409
1. Absorption	409
2. Distribution	409
a) Protein Binding	409
3. Elimination	409
a) Metabolism	409
b) Elimination Parameters	410
4. Clinical Pharmacokinetics	410
IV. Interactions	411
V. Adverse Effects	411
F. Clonazepam	411
I. Chemistry and Use	411
1. Chemistry	411
2. Use	412
II. Pharmacodynamics	412
1. Tolerance	412
III. Pharmacokinetics	413
1. Absorption	413
2. Distribution	413

3. Elimination	413
a) Metabolism	413
b) Elimination Parameters	413
IV. Interactions	414
V. Adverse Effects	414
G. Lorazepam	414
H. Nitrazepam	415
I. Midazolam	415
References	416

CHAPTER 16

Gabapentin

F.J.E. VAJDA	425
A. Introduction	425
B. Chemistry and Use	425
I. Chemical Structure and Properties	425
II. Analytical Methods for Measuring Gabapentin	426
III. Use	426
C. Pharmacodynamics	426
I. Biochemical Pharmacology	426
1. Effects on GABAergic Mechanisms	426
a) Effects on GABA Accumulation	427
b) Effects on GABA and Glutamate Metabolic Pathways	427
c) Effects on Receptors and Ion Channels	427
2. Effects on Membrane Amino Acid Transport	428
3. Studies on the Gabapentin Binding Site in Animal Brains	429
a) Distribution of Gabapentin Specific Binding Sites	430
4. Overview of Biochemical Pharmacology	430
II. Studies at a Cell or Tissue Level	430
1. Hippocampal Slices	431
2. Cultured Neurons	431
III. Animal Models of Epilepsy	431
1. Spectrum of Activity	431
2. Standard Seizure Models in Mice and Rats	432
a) Maximal Electroshock Testing	432
b) Seizures Induced by Glutamate, Aspartate and Kainic Acid	432
c) Hippocampal Kindled Seizures	432
d) Audiogenic Seizures in Mice	433

e) Seizures in the Photosensitive Baboon	433
f) Reflex Epilepsy	433
g) Classical Absences	433
IV. Antinociceptive Effects	433
V. Antispasticity Effects	433
VI. Human Studies	434
D. Pharmacokinetics	434
I. Pharmacokinetics in Animals	434
II. Pharmacokinetics in Humans	435
1. Absorption and Bioavailability	435
2. Distribution	435
a) Brain, CSF and Plasma Gabapentin Concentration Relationships	435
3. Elimination	436
a) Metabolism	436
b) Elimination Parameters	436
4. Clinical Pharmacokinetics	436
a) Plasma Concentration-Dose Relationships	436
b) Effects of Food, Multiple Dosing, Age and Disease	437
c) Gabapentin and Renal Function	437
d) Plasma Gabapentin Concentrations and Therapeutic Effects	437
E. Interactions	437
I. Effect of Gabapentin on Other Drugs	437
1. Other Antiepileptic Drugs	438
a) Multiple Drug Interactions	438
2. Oral Contraceptives	438
II. Effects of Other Drugs on Gabapentin	438
F. Adverse Effects	439
I. Animal Studies	439
1. Acute Exposure	439
2. Subacute Exposure	439
3. Chronic Exposure	439
4. Mutagenicity	439
5. Carcinogenicity	439
6. Teratogenicity	440
II. Human Studies	440
1. Add-on Pivotal Placebo-Controlled Studies in Refractory Patients	440
2. Monotherapy Trials in Previously Untreated Patients	440
3. Particular Adverse Effects in Humans	440
a) Quality of Life	440

4. Overdosage	441
5. Laboratory Abnormalities	441
6. Pregnancy	441
References	441

CHAPTER 17

Tiagabine

S.C. SCHACHTER. With 3 Figures	447
A. Introduction	447
B. Chemistry and Use	447
C. Pharmacodynamics	448
I. Biochemical Pharmacology	448
II. Electrophysiology	448
III. Animal Seizure Models	449
1. Electrically and Chemically Induced Epilepsy Models	449
2. Genetic Epilepsy Models	450
3. Anxiolytic Effects	450
4. Analgesic Effects	450
5. Effect on Cerebral Ischaemia	450
IV. Human Studies	450
1. Adult Add-on, Parallel-Design Trials	451
a) Study Designs	451
b) Enrolment Information	451
c) Results	451
2. Open-label, Long-term Treatment	452
3. Monotherapy Studies	453
a) Dose-Ranging, Tiagabine-Substitution Study	453
b) Multicentre High-Versus Low-Dose Study	454
4. Paediatric Trials	454
D. Pharmacokinetics	454
I. Animal Pharmacokinetics	454
II. Human Pharmacokinetics	455
1. Absorption and Bioavailability	455
2. Distribution	455
3. Elimination	455
a) Metabolism	455
b) Elimination Parameters	456
4. Applied Pharmacokinetics	456
5. Special Patient Groups	456
a) Hepatic and Renal Impairment	456
b) The Elderly and Children	456
E. Interactions	456
I. Pharmacodynamic Interactions	456

II. Pharmacokinetic Interactions	457
1. Effect of Tiagabine on the Pharmacokinetics of Other Drugs	457
2. Effects of Other Drugs on the Pharmacokinetics of Tiagabine	457
F. Adverse Effects	457
I. Animal Animal Toxicology	457
1. Acute Toxicity	457
2. Chronic Toxicity	457
3. Teratogenicity, Carcinogenicity, Mutagenicity	458
II. Human Studies	458
1. Add-on, Parallel-Group Studies	458
2. Monotherapy Trials	459
3. Long-term Studies	459
4. Special Safety Issues in Humans	459
a) Death	459
b) Rash, Psychosis, Status Epilepticus	459
c) Overdosage	460
d) Laboratory Values	460
e) Neuropsychological Function and Cognitive Effects	460
f) Pregnancy	460
References	461

CHAPTER 18

Topiramate

D. HEANEY and S. SHORVON. With 1 Figure	465
A. Introduction	465
B. Chemistry	465
C. Pharmacodynamics	466
I. Animal Models of Epilepsy	466
II. Biochemical Pharmacology	466
1. Na ⁺ Channels	466
2. GABA-Mediated Cl ⁻ Influx	467
3. Glutamate Receptors	467
4. Carbonic Anhydrase	468
5. Other Actions	468
III. Toxicology	468
1. Systemic Toxicity	468
2. Carcinogenicity	469
3. Reproductive and Teratology Studies	469
IV. Human Studies	469
1. Placebo-Controlled Double-blind Add-on Trials	469
2. Non-Controlled Add-on Trials	472

3. Monotherapy Studies	472
4. Add-on Therapy for Generalized Seizures	473
5. The Lennox-Gastaut Syndrome	473
D. Pharmacokinetics	474
I. Absorption	474
II. Distribution	474
III. Elimination	475
1. No Interacting Drug Present	475
2. Interacting Drugs Present	475
IV. Special Situations	476
E. Interactions	476
I. Pharmacodynamic Interactions	476
II. Pharmacokinetic Interactions	476
1. Effects of Other Drugs on Topiramate	476
2. Effects of Topiramate on Various Drugs	476
a) Antiepileptic Drugs	476
b) Other Drugs	477
F. Adverse Effects	478
G. Clinical Use	479
I. Indications	479
II. Dosage and Administration	479
1. Dosage Titration	479
2. Patient Monitoring	480
3. Overdosage	480
4. Discontinuation of Topiramate	480
H. Conclusions	480
References	481

CHAPTER 19

Zonisamide

I.E. LEPPIK	485
A. Chemistry and Use	485
B. Pharmacodynamics	485
I. Studies in Animals	485
II. Studies in Humans	486
1. Efficacy in Localization-Related Epilepsies	486
2. Efficacy in Generalized Epilepsies	488
III. Measurement in Biological Fluids	489
C. Pharmacokinetics	489
I. Absorption	490
II. Distribution	490
III. Elimination	490
1. Elimination Parameters	490
2. Metabolism and Excretion	491

D. Interactions	491
I. Pharmacokinetic Interactions	491
E. Adverse Effects	493
I. Clinical Trials	493
II. Overdosage	494
III. Teratogenicity	495
F. Dose and Administration	495
References	495

CHAPTER 20

Felbamate

W.H. THEODORE	499
A. Introduction	499
B. Chemistry and Use	499
C. Pharmacodynamic Studies	499
I. Animal Models of Epilepsy	499
II. Biochemical Actions	500
III. Human Studies	501
1. Partial Epilepsy	501
2. Generalized Epilepsy	501
D. Pharmacokinetics	503
I. Absorption	503
II. Distribution	503
III. Elimination	503
E. Interactions	504
F. Adverse Effects	505
I. Dose-Related Adverse Effects	505
II. Idiosyncratic Adverse Effects	506
G. Use of Felbamate in Practice	507
I. Role of Felbamate Blood Levels	507
II. Managing Drug Interactions	508
III. Stopping Felbamate	508
H. Conclusions	509
References	509

CHAPTER 21

Drugs Under Clinical Trial

E. PERUCCA. With 4 Figures	515
A. Introduction	515
B. Levetiracetam	516
I. Chemistry	516
II. Pharmacodynamics	516

1. Anticonvulsant Activity in Animal Models	516
2. Mechanism of Action	517
3. Other Pharmacological Effects and Toxicology Data	518
III. Pharmacokinetics	518
IV. Drug Interactions	519
V. Antiepileptic Efficacy and Adverse Effects	519
C. Losigamone	520
I. Chemistry	520
II. Pharmacodynamics	520
1. Anticonvulsant Activity in Animal Models	520
2. Mechanism of Action	521
3. Other Pharmacological Effects and Toxicology Data	523
III. Pharmacokinetics	523
IV. Drug Interactions	524
V. Antiepileptic Efficacy and Adverse Effects	525
D. Remacemide	525
I. Chemistry	526
II. Pharmacodynamics	526
1. Anticonvulsant Activity in Animal Models	526
2. Mechanism of Action	527
3. Other Pharmacological Effects and Toxicology Data	528
III. Pharmacokinetics	529
IV. Drug Interactions	530
V. Antiepileptic Efficacy and Adverse Effects	531
E. Rufinamide	531
I. Pharmacodynamics	532
II. Pharmacokinetics and Drug Interactions	532
III. Antiepileptic Efficacy and Adverse Effects	533
F. Stiripentol	533
I. Chemistry	533
II. Pharmacodynamics	533
1. Anticonvulsant Activity in Animal Models	533
2. Mechanism of Action	534
3. Other Pharmacological Effects and Toxicology Data	534
III. Pharmacokinetics	535
IV. Drug Interactions	536
V. Efficacy and Adverse Effects	536
G. Drugs in Early Clinical Development	537
I. 534U87	537
II. Abecarnil	537
III. Anti-epilepsirine	538
IV. AWD-140-190	538
V. D-2916 (Soretolide)	538
VI. D-23129 (Retigabine)	538
VII. Dezinamide	539

VIII. Ganaxolone	540
IX. Isobutyl-GABA (Pregabalin)	540
X. LY300164	541
XI. Monohydroxycarbazepine	541
XII. PNU-151774	542
XIII. <i>N</i> -Valproyl-glycinamide	542
XIV. SB-204269	543
H. Conclusion	543
References	543

CHAPTER 22

Anticonvulsant Combinations and Interactions

P.N. PATSALOS	553
A. Introduction	553
B. Extent of the Problem	553
C. Pharmacokinetic Interactions	554
I. Cytochrome P450	555
D. Pharmacodynamic Interactions	558
E. Interactions of the Generally Available Anticonvulsant Drugs ...	558
I. Pharmacokinetic Interactions	558
1. Phenobarbitone	558
a) Interactions Affecting Phenobarbitone	558
α) Valproic Acid	558
β) Phenytoin	559
γ) Miscellaneous Interactions	559
b) Interactions Where Phenobarbitone Affects Other Drugs	561
α) Anticoagulants	561
β) Calcium Antagonists	562
γ) Oral Contraceptives	562
δ) Paracetamol	562
ϵ) Valproic Acid	562
ζ) Miscellaneous Interactions	562
2. Phenytoin	563
a) Interactions Affecting Phenytoin	563
α) Alcohol	563
β) Amiodarone	563
γ) Antiulcer Agents	564
δ) Carbamazepine	565
ϵ) Isoniazid	565
ζ) Phenobarbitone	565
η) Valproic Acid	566
θ) Miscellaneous Interactions	566

b) Interactions Where Phenytoin Affects Other	
Drugs	567
α) Anticoagulant Drugs	567
β) Dexamethasone	567
γ) Theophylline	567
δ) Miscellaneous Interactions	567
3. Primidone	569
a) Interactions Affecting Primidone	569
b) Interactions Where Primidone Affects Other	
Drugs	569
4. Ethosuximide	569
a) Interactions Affecting Ethosuximide	569
b) Interactions Where Ethosuximide Affects Other	
Drugs	570
5. Carbamazepine	570
a) Interactions Affecting Carbamazepine	570
α) Antibiotics	570
β) Antidepressants	570
γ) Anticonvulsant Drugs (Enzyme-Inducing)	571
δ) Calcium Channel Blockers	571
ε) Cimetidine	571
ζ) Imidazole Drugs	571
η) Valproic Acid	571
θ) Miscellaneous Interactions	572
b) Interactions Where Carbamazepine Affects Other	
Drugs	572
6. Diazepam	573
a) Interactions Affecting Diazepam	573
b) Interactions Where Diazepam Affects Other	
Drugs	573
7. Clonazepam	573
a) Interactions Affecting Clonazepam	573
b) Interactions Where Clonazepam Affects Other	
Drugs	574
8. Valproic Acid	574
a) Interactions Affecting Valproic Acid	574
b) Interactions Where Valproic Acid Affects Other	
Drugs	574
9. Clobazam	575
a) Interactions Affecting Clobazam	575
b) Interactions Where Clobazam Affects Other	
Drugs	575
II. Pharmacodynamic Interactions	575
1. Interactions Between Anticonvulsant Drugs	575
2. Interactions Between Anticonvulsant Drugs and	
Other Drugs	576

F. Interactions of the Recently Licensed Anticonvulsant Drugs	576
I. Pharmacokinetic Interactions	576
1. Vigabatrin	576
a) Interactions Affecting Vigabatrin	576
b) Interactions Where Vigabatrin Affects Other Drugs	577
2. Lamotrigine	577
a) Interactions Affecting Lamotrigine	577
b) Interactions Where Lamotrigine Affects Other Drugs	577
3. Gabapentin	579
a) Interactions Affecting Gabapentin	579
b) Interactions Where Gabapentin Affects Other Drugs	579
4. Topiramate	579
a) Interactions Affecting Topiramate	579
b) Interactions Where Topiramate Affects Other Drugs	579
5. Felbamate	580
a) Interactions Affecting Felbamate	580
b) Interactions Where Felbamate Affects Other Drugs	580
6. Oxcarbazepine	580
a) Interactions Affecting Oxcarbazepine	581
b) Interactions Where Oxcarbazepine Affects Other Drugs	581
7. Tiagabine	581
a) Interactions Affecting Tiagabine	581
b) Interactions Where Tiagabine Affects Other Drugs	582
8. Zonisamide	582
a) Interactions Affecting Zonisamide	582
b) Interactions Where Zonisamide Affects Other Drugs	582
II. Pharmacodynamic Interactions	582
1. Interactions Between Anticonvulsant Drugs	582
2. Interactions Between Anticonvulsant Drugs and Other Drugs	582
G. Conclusions	582
References	583

CHAPTER 23

The Use of Antiepileptic Drugs in Clinical Practice

M.J. EADIE	589
----------------------	-----

A. Introduction	589
B. Changes in Antiepileptic Drug Use for Epilepsy	589
I. Increased Knowledge of the Natural History of Epilepsy	589
II. A More Critical Application of Pharmacokinetic Concepts	590
III. The Availability of New Antiepileptic Drugs	591
IV. A Better Understanding of the Mechanisms of Action of Antiepileptic Drugs	591
V. The Maturing of the Surgical Therapy of Epilepsy	592
C. The Decision to Prescribe Antiepileptic Drug Therapy	592
I. Prevention of Anticipated (Usually Situation-Related) Seizures	592
II. After a Solitary Seizure	593
III. Definite Epilepsy	594
D. The Choice of an Antiepileptic Drug	594
E. Initiating Drug Therapy	596
F. Continuing Drug Therapy	600
I. No Further Seizures and No Adverse Effects Occur	600
II. Adverse Effects Occur	600
III. Seizures Continue Despite Therapy	600
IV. Antiepileptic Drug Monotherapy Fails	601
1. Antiepileptic Drug Combinations	601
2. Pharmacokinetic Interactions Between Anticonvulsants	602
V. The Patient's Physiological Status Alters	603
1. Age	603
2. Menstrual Cycle	604
3. Pregnancy	604
4. Intercurrent Illness	606
VI. Status Epilepticus Occurs	606
1. Generalized Convulsive Status Epilepticus	607
2. Non-convulsive Status Epilepticus	607
G. Duration of Therapy	608
H. Withdrawal of Therapy	609
I. Use of Antiepileptic Drugs for Indications Other than Epilepsy	609
References	610
Subject Index	615

Antiepileptic Drugs

Pharmacology and Therapeutics

Eadie, M.J.; Vajda, F. (Eds.)

1999, XXXVIII, 631 p., Hardcover

ISBN: 978-3-540-65374-5